Amphista Therapeutics discloses first details of its TEAD Targeted Glue™ program and unveils new mechanism of action for TEAD degradation via FBXO22 First disclosure of a novel mechanism of action for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback